cambridgeindependent1d
AstraZeneca revenues rise to $54bn as it enters ‘unprecedented’ period for company
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
Zawya2h
Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care
AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
FierceBiotech1d
Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...
The inside story of Britain’s failure to clinch £450mn AstraZeneca deal
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Sumitomo Mitsui Trust Group Inc. Has $5.58 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...
AstraZeneca upgraded to Buy from Neutral at UBS
UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...
AstraZeneca's cancer drug tops list of new brands launched in 2024
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Havant MP Alan Mak demands to know why Labour Government walked away from £450m AstraZeneca investment deal
Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...
Hosted on MSN4h
AstraZeneca offered 'significant' sum, says minister
The government has defended its negotiations with AstraZeneca, after the pharmaceutical giant ditched a planned £450m investment last week, blaming a shortfall in government funding. Science ...